OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022 at 10:17 pm
Share
OBI Pharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 1.08 million compared to TWD 2.79 million a year ago. Net loss was TWD 387.53 million compared to TWD 324.87 million a year ago. Basic loss per share from continuing operations was TWD 1.7 compared to TWD 1.64 a year ago. Basic loss per share was TWD 1.7 compared to TWD 1.64 a year ago.
For the nine months, sales was TWD 4.2 million compared to TWD 16.26 million a year ago. Net loss was TWD 1,036.17 million compared to TWD 971.97 million a year ago. Basic loss per share from continuing operations was TWD 4.72 compared to TWD 4.89 a year ago. Basic loss per share was TWD 4.72 compared to TWD 4.89 a year ago.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
OBI PHARMA, INC. 
